Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3556050 for Osteoarthritis Pain
NCT04627038Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in osteoarthritis (OA) comparing LY3556050 with Placebo (2 arms). Primary endpoint: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) at 8 weeks. Started Nov 2020; status: completed.
02
Drugs
ly3556050
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04627038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627038.